TY - JOUR
T1 - Maintenance in gastric cancer
T2 - New life for an old issue?
AU - Roviello, Giandomenico
AU - Rodriquenz, Maria Grazia
AU - Aprile, Giuseppe
AU - D'Angelo, Alberto
AU - Roviello, Franco
AU - Nobili, Stefania
AU - Mini, Enrico
AU - Sarno, Italo
AU - Polom, Karol
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/30
Y1 - 2021/4/30
N2 - The interest in maintenance therapy for patients with advanced cancers has been rapidly growing. Maintenance therapy is a useful strategy that may strengthen results of induction therapy thus extending survival and preserving the quality of life (QoL) with less toxicity. Maintenance also represents a suitable setting to investigate novel agents. The value of maintenance therapy after first-line chemotherapy has been well established in several solid tumours, such as colorectal, lung, breast, and ovarian cancer in which it is largely adopted. To date, there is no established role for maintenance therapy following first-line chemotherapy for advanced gastric cancer (GC). This review summarizes the current knowledge regarding maintenance strategies in advanced GC exploring cytotoxic agents, biologic agents and immunotherapy. We also critically review new issues to optimize randomized clinical trials for maintenance therapies and suggest clinical consideration to guide a personalized approach in daily clinical practice for this setting.
AB - The interest in maintenance therapy for patients with advanced cancers has been rapidly growing. Maintenance therapy is a useful strategy that may strengthen results of induction therapy thus extending survival and preserving the quality of life (QoL) with less toxicity. Maintenance also represents a suitable setting to investigate novel agents. The value of maintenance therapy after first-line chemotherapy has been well established in several solid tumours, such as colorectal, lung, breast, and ovarian cancer in which it is largely adopted. To date, there is no established role for maintenance therapy following first-line chemotherapy for advanced gastric cancer (GC). This review summarizes the current knowledge regarding maintenance strategies in advanced GC exploring cytotoxic agents, biologic agents and immunotherapy. We also critically review new issues to optimize randomized clinical trials for maintenance therapies and suggest clinical consideration to guide a personalized approach in daily clinical practice for this setting.
KW - First-line
KW - Gastric cancer
KW - Maintenance
UR - http://www.scopus.com/inward/record.url?scp=85103051848&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2021.103307
DO - 10.1016/j.critrevonc.2021.103307
M3 - Review article
C2 - 33753249
AN - SCOPUS:85103051848
SN - 1040-8428
VL - 160
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103307
ER -
